Siren L.L.C. Has $16.57 Million Stake in Neumora Therapeutics, Inc. $NMRA

Siren L.L.C. boosted its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 35.1% in the first quarter, Holdings Channel reports. The firm owned 8,497,822 shares of the company’s stock after purchasing an additional 2,209,039 shares during the quarter. Siren L.L.C.’s holdings in Neumora Therapeutics were worth $16,571,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Invesco Ltd. grew its holdings in shares of Neumora Therapeutics by 151.1% in the 1st quarter. Invesco Ltd. now owns 123,655 shares of the company’s stock valued at $124,000 after acquiring an additional 74,406 shares in the last quarter. AQR Capital Management LLC bought a new stake in Neumora Therapeutics during the first quarter worth about $463,000. Russell Investments Group Ltd. boosted its position in Neumora Therapeutics by 2,898.1% during the second quarter. Russell Investments Group Ltd. now owns 73,812 shares of the company’s stock valued at $56,000 after purchasing an additional 71,350 shares during the last quarter. Marshall Wace LLP acquired a new position in Neumora Therapeutics during the second quarter valued at approximately $183,000. Finally, Federated Hermes Inc. grew its stake in Neumora Therapeutics by 10.4% in the second quarter. Federated Hermes Inc. now owns 314,119 shares of the company’s stock valued at $230,000 after purchasing an additional 29,543 shares in the last quarter. 47.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NMRA has been the topic of a number of analyst reports. HC Wainwright dropped their price objective on Neumora Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Friday, July 17th. Needham & Company LLC lowered their target price on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Royal Bank Of Canada cut their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Guggenheim reiterated a “buy” rating and issued a $14.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.57.

Neumora Therapeutics Stock Performance

NMRA opened at $1.56 on Friday. The company has a quick ratio of 5.09, a current ratio of 5.09 and a debt-to-equity ratio of 0.75. The stock has a market cap of $289.04 million, a price-to-earnings ratio of -1.17 and a beta of 2.74. Neumora Therapeutics, Inc. has a 12-month low of $0.83 and a 12-month high of $3.65. The business has a 50 day moving average of $1.66 and a 200-day moving average of $2.17.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. On average, equities research analysts expect that Neumora Therapeutics, Inc. will post -0.93 earnings per share for the current year.

Neumora Therapeutics Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.